Press releases

  • Reset
Avance Clinical Expands Specialist CNS, Cardiometabolic, and Rare Diseases CRO Services in Europe  with Julius Clinical

28 May 2024

Avance Clinical Expands Specialist CNS, Cardiometabolic, and Rare Diseases CRO Services in Europe with Julius Clinical

Avance Clinical has signed a Memorandum of Understanding (MOU) with Julius Clinical, a leading CNS and rare diseases specialist CRO with extensive site relationships in the region.

Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia

7 May 2024

Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia

Oragenics, Inc. (NYSE American: OGEN), a pioneer in developing innovative intranasal pharmaceuticals for neurological disorders, today announced a partnership with Avance Clinical, a leading Contract Research Organization (CRO), to conduct a Phase II clinical trial in Australia

SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential DiseaseModifying Treatment for Type 1 Diabetes

29 November 2023

SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential DiseaseModifying Treatment for Type 1 Diabetes

SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for disease-modification of Type 1 Diabetes (T1D) through delaying the onset and/or progression of the disease, today announced that the first participants of a HUMAN trial (Fully HUman anti-thymocyte biologic in first-in-MAN clinical study) have been dosed in Australia.

Proven industry
experience & expertise

500+

Studies in the past 5 years

330+

Experienced team members

18k+

Participants past 5 years

30

Years of CRO experience